Back to Search
Start Over
Bioenergetic modulators hamper cancer cell viability and enhance response to chemotherapy
- Source :
- Journal of Cellular and Molecular Medicine, Repositório Científico de Acesso Aberto de Portugal, Repositório Científico de Acesso Aberto de Portugal (RCAAP), instacron:RCAAP
- Publication Year :
- 2018
- Publisher :
- Wiley, 2018.
-
Abstract
- Gliomas are characterized by a marked glycolytic metabolism with a consequent production of massive amounts of lactate, even in the presence of normal levels of oxygen, associated to increased invasion capacity and to higher resistance to conventional treatment. This work aimed to understand how the metabolic modulation can influence tumour aggressive features and its potential to be used as complementary therapy. We assessed the effect of bioenergetic modulators (BMs) targeting different metabolic pathways in glioma cell characteristics. The in vivo effect of BMs was evaluated using the chicken chorioallantoic membrane model. Additionally, the effect of pre-treatment with BMs in the response to the antitumour drug temozolomide (TMZ) was analysed in vitro. Cell treatment with the BMs induced a decrease in cell viability and in migratory/invasion abilities, as well as modifications in metabolic parameters (glucose, lactate and ATP) and increased the cytotoxicity of the conventional drug TMZ. Furthermore, all BMs decreased the tumour growth and the number of blood vessels in an in vivo model. Our results demonstrate that metabolic modulation has the potential to be used as therapy to decrease the aggressiveness of the tumours or to be combined with conventional drugs used in glioma treatment.<br />Project NORTE‐01‐0145‐FEDER‐000013, supported by the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal Partnership Agreement, through the European Regional Development Fund (FEDER), and through the Competitiveness Factors Operational Programme (COMPETE) and by National funds, through the Foundation for Science and Technology (FCT), under the scope of the project POCI‐01‐0145‐FEDER‐007038. This work was also supported by an internal CESPU project 02‐GBMC‐CICS‐2011 MetabRes_CESPU_2017. DT‐V received a fellowship from FCT (ref. SFRH/BD/103025/2014). SG received a fellowship from FCT (ref. SFRH/BPD/117858/2016)<br />info:eu-repo/semantics/publishedVersion
- Subjects :
- 0301 basic medicine
glycolytic inhibitors
warburg effect
Medicina Básica [Ciências Médicas]
Cell
03 medical and health sciences
0302 clinical medicine
In vivo
glioma
Glioma
medicine
Cytotoxicity
Science & Technology
drug resistance
Temozolomide
Chemistry
tumour bioenergetic
Original Articles
Cell Biology
medicine.disease
Warburg effect
3. Good health
Chorioallantoic membrane
030104 developmental biology
medicine.anatomical_structure
Drug resistance
030220 oncology & carcinogenesis
Ciências Médicas::Medicina Básica
Cancer cell
Cancer research
Molecular Medicine
Original Article
Tumour bioenergetic
Glycolytic inhibitors
medicine.drug
Subjects
Details
- ISSN :
- 15824934 and 15821838
- Volume :
- 22
- Database :
- OpenAIRE
- Journal :
- Journal of Cellular and Molecular Medicine
- Accession number :
- edsair.doi.dedup.....b3ec09dd17a15393f45463315299caa4
- Full Text :
- https://doi.org/10.1111/jcmm.13642